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Cardiorenal syndrome (CRS) clinical types, prevalence, aetiology, and acute cardiovascular morbidity impact on the outcome
of acute kidney function perturbation were determined. Forty-seven of 101 (46.53%) patients with perturbed kidney function
had CRS. Types 3 and 5 CRS were found in 10 and 37 patients, respectively. Type 3 CRS was due to acute glomerulonephritis
(AGN; n = 7), captopril (n = 1), frusemide (n = 1), and hypovolaemia (n = 1). Malaria-associated haemoglobinuria (n = 20),
septicaemia (n = 11), lupus nephritis (n = 3), tumour lysis syndrome (n = 2), and acute lymphoblastic leukaemia (n = 1) caused
Type 5 CRS. The cumulative mortality in hypertensive CRS was similar to nonhypertensive CRS (51.4%versus40.9%; P = .119).
Mortality in CRS and non-CRS was similar (45.7%versus24.5%; P = .053). Type 5 survived better than type 3 CRS (66.7% versus
12.5%; P = .001). Risk factors for mortality were Type 3 CRS (P = .001), AGN-associated CRS (P = .023), dialysis requiring CRS
(P = .008), and heart failure due to causes other than anaemia (P = .003). All-cause-mortality was 34.2%. Preventive measures
aimed at the preventable CRS aetiologies might be critical to reducing its prevalence.
1.Introduction
The cardiorenal syndrome (CRS) is a disorder of the heart
and kidneys whereby acute or chronic dysfunction in one
organ may induce acute or chronic dysfunction of the other
[1,2];itisarecognizedmorbidityandmortalitymultiplierin
critically ill children [3]. While heart failure (HF) is a clinical
syndrome in which heart disease reduces cardiac output,
increasesvenouspressures,andisaccompaniedbymolecular
abnormalities that cause progressive deterioration of the
failing heart and premature myocardial cell death [4], acute
kidney injury (AKI) is an abrupt clinical and/or laboratory
manifestation of kidney dysfunction usually within 48 hours
of bilateral kidney insult of any kind. Failure of both organs
commonly coexists in critically ill children [5–7]. Congestive
HF is a highly prevalent AKI comorbidity and a major
indication for acute dialysis in children [5]. Recently, the
7th Acute Dialysis Quality Initiative (ADQI) workgroup
classiﬁed CRS into ﬁve distinct clinical types, [1, 2]n a m e l y :
acute CRS (Type 1)—acute worsening of heart function
leading to kidney injury and/or dysfunction; chronic CRS
(Type 2)—chronic abnormalities in heart function leading
to kidney injury and/or dysfunction; acute renocardiac
syndrome (Type 3)—acute worsening of kidney function
(AKI) leading to heart injury and/or dysfunction; chronic
renocardiac syndrome (Type 4)—chronic kidney disease
leading to heart injury, disease, and/or dysfunction, and
secondary CRS (Type 5)—systemic conditions leading to
simultaneous injury and/or dysfunction of heart and kidney.
While a lot of data have been published on chronic kidney
disease as risk factor for cardiovascular morbidity and mor-
talityinbothchildrenandadults(reviewedin[1–3]),thereis
paucity of speciﬁc data on acute cardiac dysfunction leading
to AKI and vice versa in children especially [8]; in this study,
an attempt was made to determine the prevalence, aetiology,
clinical types of CRS, and impact of acute cardiovascular
morbidity on the outcome of childhood acute kidney injury.
2. Patients andMethods
Clinical charts of patients managed for AKI-associated HF
and acute glomerulonephritis (AGN)—associated HF in our2 International Journal of Nephrology
paediatric nephrology and hypertension unit were reviewed.
It was a retrospective case-control study; patients who had
either AKI or AGN without HF served as control (non-CRS).
The objectives were to determine the prevalence, aetiology,
clinical types of CRS, and impact of acute cardiovascular
morbidity on the outcome of childhood AKI. The study
period ranged between January 2005 and December 2009.
Our hospital’s Ethics and Research Committee approved the
research protocol. The study conformed to the provisions of
the revised Declaration of Helsinki, Edinburg, 2000.
Analyzed data were age, gender, anthropometry, vital
signs, admission diagnosis, time of onset of HF and AKI,
ﬁnal AKI stage, hospitalization period, follow-up duration,
urine output, and management outcome. Relevant labora-
tory investigations including serum creatinine (Scr) both at
baseline and at followup were reviewed.
2.1. Deﬁnitions. AKI was diagnosed based on the acute
kidney injury network (AKIN) criteria [9]a sa na b s o l u t e
increase in serum creatinine (Scr) level within 48 hours
of bilateral kidney insult by ≥0.3mg/dL (≥26.4µmol/L)
or a 50% (1.5-fold) increase or more in Scr from the
baseline. AKI was staged using the creatinine criteria of
the AKIN workgroup [9]—Stage 1 AKI (AKI-1): rise in
Scr by ≥0.3mg/dL (26.4µmol/L) or an increase of >150–
200% (1.5- to 2-fold increase) from the baseline; Stage 2
AKI (AKI-2): rise in Scr by >200–300% (>2- to 3-fold
increase) from baseline; Stage 3 AKI (AKI-3): rise in Scr
by >300% (>3-fold) from the baseline or Scr ≥ 4.0mg/dL
(≥354µmol/L) with an acute rise of at least 0.5mg/dL
(44µmol/L). Nonoliguric AKI was deﬁned as urine output
that was persistently >0.5mL/kg/hour in the setting of an
abnormal Scr level. Anuric AKI was deﬁned as the urine
output that was <0.039mL/kg/hr for 12hr or more in the
absence of an obstructive uropathy. AKI was staged based
on the peak Scr (pScr) level. pScr was the highest Scr level
reached in any patient either before death or before gradual
return to normal. Those who were initially diagnosed AKI-
1 or AKI-2 but later required dialyses were upgraded to
AKI-3 as recommended [9]. The predictive eGFR equation
with corrections for age, gender, and race derived by the
Modiﬁcation of Diet in Renal Disease (MDRD) [10]s t u d y
group was used to determine the baseline Scr for patients
who do not have baseline Scr as recommended by the 2nd
ADQI workgroup [11]. For such patients, the 2nd ADQI
recommended that normal estimated glomerular ﬁltration
rate (eGFR) ranging from 75 to 100mL/min per 1.73m2
should be used. In this study, all AKI patients without
baseline measure of renal function were assumed to have
eGFRvalueof100mL/min/1.73m2.BytheMDRDequation,
eGFR = 186 × ([Scr]
−1.154 × Age
−0.203 × 0.742 (if female) ×
1.210 (if black)) [10].
Heart failure was diagnosed based on a combination of
dyspnoea, tachycardia (heart rate >160, >150, >140, >120,
and>100beats/minforinfants,childrenaged1–3,4–5,6–12,
and above 12 years, resp.), tachypnoea (respiratory rate >60,
>40, >34, >30, and >20breathes/min for infants, children
aged 1–3, 4–5, 6–12, and above 12 years, resp.), tender
hepatomegaly, and feeding diﬃculty with or without chest
X-ray evidence of cardiomegaly (abnormal cardiothoracic
ratio >60% in under ﬁves and >55% in older children).
HF severity was assessed and classiﬁed according to the
modiﬁed Ross heart failure classiﬁcation for children [12]—
Class I heart failure: asymptomatic; Class II heart failure:
mild tachypnoea or diaphoresis with feeding in infants or
dyspnoeaonexertioninolderchildren;ClassIIIheartfailure:
marked tachypnoea or diaphoresis with feeding in infants,
marked dyspnoea on exertion, and prolonged feeding times
with growth failure; Class IV heart failure: symptoms such
as tachypnoea, retractions, grunting, or diaphoresis at rest.
Hypertensionwasdiagnosedbasedontheupdateofthe1987
Task Force Report on High Blood Pressure in Children and
Adolescents [13]. CRS was classiﬁed based on the 7th ADQI
consensus conference report [2].
The inclusion criteria were patients with acute pertur-
bation of kidney function (AKI or AGN or both) with or
without HF. Patients with chronic renal failure or acute-on-
chronic renal failure were excluded. To determine the impact
of HF on survival, mortality was compared between CRS
(AKI + HF and AGN + HF) and non-CRS patients. The
cumulative all-cause-mortality and CRS-speciﬁc mortality
rates were determined.
2.2.StatisticalAnalysis. Descriptive statistics usedcomprised
mean, standard deviation, median, percentages, and pro-
portions. The comparative statistics were Student’s t-test,
Chi-square test, Cox regression analysis for hazard ratio
(HR), Wilcoxon statistics, Kaplan-Meier survival analysis,
and Mantel-Cox pairwise comparisons (Log-rank test) using
the SPSS 15.0 for Windows evaluation version (2006, SPSS
Inc.). A P-value <.05 was regarded as statistically signiﬁcant.
3. Results
A total of 101 patients with acute perturbation of kidney
function, namely, AKI and AGN were reviewed. There were
7 and 94 acute glomerulonephritis (AGN) and AKI patients,
respectively. Forty seven of 101 (46.53%) patients with
abnormal kidney function had HF-cardiorenal syndrome.
HF wasof theseverestclass (ClassIV) in alltheCRS patients.
Age, gender, and blood pressure data are summarized in
Table 1. Median age of 5.0 years (0.06–15.0) for controls was
similar to that for CRS, P = .689. Types 3 and 5 CRS were
found in 10 (21.3%) and 37 (78.7%) patients, respectively.
Table 2 shows the relationship between the two CRS types
in this study and their aetiologies. Two of 7 patients whose
CRS was due to AGN had no associated AKI (AGN–AKI)
while the remaining 5 had associated AKI. The pScr was
6.11 ± 4.0( 0 .95–17.32)mg/dL. AKI-1, AKI-2, and AKI-3
accounted for 4 (8.50%), 5 (10.60%), and 36 (76.60%) CRS
cases, respectively, while AGN-AKI accounted for the rest.
Twenty-two (46.80%) of the CRS patients had oliguric AKI
while nonoliguric and anuric AKI were seen in 11 (23.40%)
and 14 (29.80%) patients, respectively. Oliguria duration in
both CRS and controls was 6.9 ± 5.54 days and 7.5 ± 4.75
days, respectively (P = .654).
A n a e m i aw a sp r e s e n ti n4 3o f4 7C R Sp a t i e n t s( 9 1 . 5 % ) .
The haematocrit ranged from 4.0 to 32.0% with the 5th,International Journal of Nephrology 3
Table 1:Demographicandclinicalcharacteristicsofthecardiorenal
syndrome patients (n = 47).
Demographic and baseline clinical
characteristics Results (%)
Age < 6 years 33 (70.21)
Age ≥ 6 years 14 (29.79)
Median age (range), years 4.0 (.3–14.5)
Gender
Male 26 (55.32)
Female 21 (44.68)
Male to female ratio 1.24:1
Number with normal blood pressure (BP)a 26 (57.8)
Systolic BP range, mmHg 60–110
5th, 50th, and 95th percentiles in mmHg 63.5, 90, and 110
Diastolic BP range, mmHg 30–70
5th, 50th, and 95th percentiles in mmHg 33.5, 50, and 70
Mean arterial pressure range, mmHg 43.3–83.3
5th, 50th, and 95th percentiles in mmHg 44.49, 66.7, and 82.85
Number with hypertension 19 (42.2)
Systolic BP range, mmHg 90–190
5th, 50th, and 95th percentiles in mmHg 90, 120, and 190
Diastolic BP range, mmHg 60–130
5th, 50th, and 95th percentiles in mmHg 60, 80, and 130
Mean arterial pressure range, mmHg 73.3–150
5th, 50th, and 95th percentiles in mmHg 73.3, 93.3, and 150
aBlood pressure data available in 45 of 47 patients.
Table 2: Relation between cardiorenal syndrome types and their
aetiologies.
Cardiorenal syndrome type and aetiology
Proportion
of patients
(%)
Type 3
Acute glomerulonephritis 7.0 (70.0)
Captopril 1.0 (10.0)
Frusemide 1.0 (10.0)
Hypovolaemic shock due to gastroenteritis 1.0 (10.0)
Type 5
Malaria-associated haemoglobinuria 20.0 (54.05)
Septicaemia 11.0 (29.73)
Lupus nephritis 3.0 (8.11)
Tumour lysis syndrome in Burkitt’s lymphoma
patients 2.0 (5.41)
Acute lymphoblastic leukaemia 1.0 (2.70)
50th, and the 95th haematocrit percentiles for the anemic
CRS being 5.2%, 15.0%, and 27.6%, respectively. Severe,
moderate, and mild anaemia occurred in 38 (88.37%), 2
(4.65%), and 3 (6.98%) patients, respectively, (P = .000).
Malaria-associated haemoglobinuria (MAH), septicaemia,
AGN, lupus nephritis and tumour lysis syndrome accounted
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Figure 1: Kaplan-Meier survival curves showing that survival was
not signiﬁcantly higher in controls than in cardiorenal syndrome
(75.5% versus 54.3%). Similarly, the survival times were not
signiﬁcantly diﬀerent.
for 20 (46.51%), 10 (23.25%), 4 (9.30%), 3 (6.97%), and
2 (4.65%) anaemia cases, respectively. Hypovolaemia due
to gastroenteritis, acute lymphoblastic leukaemia, captopril,
and frusemide accounted for one (2.33%) case each, (P =
.000).Anaemiawasabsentin1septicaemiaand3AGNcases.
3.1. Followup and Outcome. The mean CRS hospitalization
period was 21.90 ± 16.42 days (controls: 25.1 ± 19.7; P =
.361).BoththeCRSandnon-CRSpatientswere,respectively,
followed for 67.2 ± 90.97 (1.0 − 398.0) days and 128.96 ±
240.61 (1.0–1319.0; P = .106) days. Survival in CRS patients
who were <6 years old was similar to older patients (14
versus 10 survivors; HR:.483, 95% CI: .157–1.488; P = .205).
Cumulative mortality was higher in hypertensive (51.4%)
than nonhypertensive (40.9%) CRS, but the diﬀerence did
not reach statistical signiﬁcance (HR:.476, 95% CI: .183–
1.240; P = .129). Survival comparison between non-CRS
(controls) and CRS patients revealed no statistically signif-
icant diﬀerence (HR:.496, 95% CI: .239–1.031; Figure 1).
Figure 2 shows that patients with Type 5 CRS survived better
than Type 3 CRS (HR:.479, 95% CI: .299–.768). The cumu-
lative survival for MAH, septicaemia, and acute glomeru-
lonephritis was 81.4%, 39.8%, and 21.4%, respectively; none
of the patients with AKI due to hypovolaemia, frusemide,
captopril, and leukaemia survived. CRS due to aetiologies
other than AGN was signiﬁcantly less associated with mor-
tality compared with CRS due to AGN (40.4% versus 78.6%;
HR: .544; 95% CI: .322–.919; P = .023). A pairwise compari-
son statistics (Wilcoxon) revealed that MAH survived signif-
icantly better than other CRS causes (P = .014). No death
occurred in AKI-1, but there were 2 and 15 deaths in AKI-2
and AKI-3, respectively; AGN-AKI had one death. Mortality
wassimilar in allAKI stages(HR: 1.872, 95% CI: .761–4.603)
aswellasinallthethreeAKItypes(HR:1.385,95%CI:.799–
2.400) of CRS. Survival comparisons among the AKI types in
both CRS and non-CRS revealed no signiﬁcant diﬀerences4 International Journal of Nephrology
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Figure 2:Kaplan-Meiersurvivalcurvesshowingsigniﬁcantlybetter
survival in Type 5 compared to Type 3 cardiorenal syndrome
(72.3% versus 12.5%).
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Figure 3: Comparisons between controls and patients with car-
diorenal syndrome with regard to survival in the acute kidney
injury (AKI) types. The number of patients surviving in oliguric,
nonoliguric, and anuric AKI was similar in both groups of patients.
(Figure 3). Figure 4 shows that mortality in nonanaemic
CRS patients was signiﬁcantly higher compared to anaemic
CRS (HR: 4.637, 95% CI: 1.496–14.370). The outcome was
signiﬁcantly better among CRS patients who required no
dialysis than those who required dialysis (HR: .284, 95%
CI:.106–.765; Figure 5). A stratiﬁcation to CRS type showed
that dialysis-requiring Type 3 CRS had signiﬁcantly higher
cumulativemortalityratethandialysis-requiringType5CRS
(100% versus 51.1%; Log rank P = .049). This was similarly
so for those not requiring dialysis (Type 3 CRS: 70.0%
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Figure 4: Kaplan-Meier survival curves comparing survival in
cardiorenal syndrome patients with anaemia and those without
anaemia. Patients with anaemia had signiﬁcantly higher survival
rate compared to nonanaemic patients (61.4% versus 25.0%).
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Figure 5: Kaplan-Meier survival curves for dialysis-requiring and
non-dialysis requiring cardiorenal syndrome patients. Dialysis-
requiring-cardiorenal syndrome had signiﬁcantly lower survival
rate compared to those who required no dialysis (35.5% versus
70.6%).
versus Type 5 CRS: 19.1% mortality; Log rank P = .039).
Further stratiﬁcation for aetiology showed poorer survival
with regards to Type 3 CRS compared to Type 5 as all
Type 3 patients who required dialysis died (n = 5); all had
AGN that was associated with poorer outcome compared
to either MAH or septicaemia (Wilcoxon, P = .001).
Eighteen CRS patients died at the end of 398 follow-up
days, while 28 survived, and one took voluntary discharge.
The cumulative CRS-speciﬁc mortality was 45.7%. ThirtyInternational Journal of Nephrology 5
patients died overall (both CRS and controls) thus bringing
the cumulative all-cause-mortality to 34.2%.
4. Discussion
ThisstudyrevealedCRSasahighlyprevalentclinicaleventin
acute perturbation of kidney function with hypertension as a
common cardiovascular comorbidity. Given the spectrum of
CRS aetiology in this study, hypertension was probably the
result of intravascular congestion brought about by oliguria
seen in 76.6% of the patients on one hand, and activation
of the renin-angiotensin-aldosterone-system following renal
hypoperfusion secondary to acute proliferative changes of
AGN on the other hand. Interestingly, hypertension was
found not to be a signiﬁcant risk factor for mortality in this
study (HR: 0.476, 95% CI: 0.183–1.240).
The acute nature of the CRS and the accompany-
ing hypertension, as well as, prompt response to anti-
hypertensive treatment, and vascular decongestion following
diuretic phase onset could be responsible for this. Left
ventricular hypertrophy and congestive HF are common in
childhood AGN and CKD with high mortality rate [7, 14–
16]. In this study, HF was highly prevalent and mortality rate
fromCRSwasequallyhighbutwasnotsigniﬁcantlydiﬀerent
from controls; this is not withstanding the fact that the HF
was of the severest class (Class IV). Anaemia is a highly
prevalent comorbidity in both AKI [5, 6, 17] and CKD [18];
it has been associated with increased severity of congestive
HF, increased hospitalization, worse cardiac function and
functional class, the need for higher doses of diuretics,
progressive worsening of renal function, and reduced quality
of life [19]. Anaemia occurred in 91.5% of our patients with
anaemia-speciﬁc mortality rate of 38.6%. Nonanaemic CRS
patients were, however, 4.6 times more likely to die than
their anaemic counterparts (95% CI: 1.496–14.370). This
is because the majority of the anaemic cases were due to
malariathatrespondedrapidlytotreatment;theacutenature
of the accompanying congestive anaemic HF that responded
promptly to blood transfusion also contributed to better
survival in the anaemic CRS compared to nonanaemic CRS
that was largely due to poor outcome septicaemia and AGN.
While AKI stage and type did not inﬂuence the outcome in
thisstudy,Type5CRSwasfoundtoprotectagainstmortality.
T h ep o s i t i v ei m p a c to fT y p e5C R So ns u r v i v a lw a sd u e
to the fact that the majority of the patients in this class
had MAH that was signiﬁcantly associated with the highest
survival rate compared to Type 3 CRS in which majority
of the patients had AGN that was signiﬁcantly associated
with very low survival rate. The fact that CRS patients who
required no dialysis survived better than those who required
dialysis (HR: 0.28; 95% CI: 0.106–0.765) could mean more
severe structural kidney pathology and dysfunction in those
needing dialysis. This was particularly more evident when
CRS was stratiﬁed for CRS types and outcome.
It is concluded that CRS was a very common clinical
event with high mortality rate in critically ill children. Com-
pared to controls, CRS mortality rate was not signiﬁcantly
higher; risk factors for mortality in CRS were CRS Type
3, AGN-associated CRS, dialysis-requiring CRS, and heart
failure not associated with anaemia. Preventive measures
aimed at some of the preventable aetiologies of CRS might
be critical to reducing its prevalence.
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